Targeted News Service

Exdensur Approved in the UK for Treatment of Asthma With Type 2 Inflammation and Chronic Rhinosinusitis With Nasal Polyps
December 16, 2025

LONDON, England, Dec. 16 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 15, 2025:

* * *

Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

* First and only ultra-long-acting biologic with twice-yearly dosing to treat respiratory diseases

* UK approval based on data from the SWIFT and ANCHOR phase III tr . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form